GlassScriptPhysician profile
Erin Duffell
NPI 1265876676
$1,768.61
in general payments reported to CMS, 2019-2025
18 companies · $79.07 in 2025
The $79.07 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $164 · 2023: $785 · 2024: $741 · 2025: $79.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $527.80 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $298.49 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $144.83 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $143.03 | 2023-2024 | |
| Novo Nordisk INC | $126.66 | 2022-2025 | Ozempic, Rybelsus, Saxenda |
| Novartis Pharmaceuticals Corporation | $123.38 | 2023-2025 | |
| Pfizer INC. | $84.40 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.63 | 2023-2024 | Synjardy, Tradjenta, Jardiance |
| Mylan Specialty L.P. | $51.91 | 2022-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $39.36 | 2022-2024 | Capvaxive |
| Amgen INC. | $34.41 | 2024-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $33.27 | 2023 | |
| Phathom Pharmaceuticals, INC. | $18.99 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $18.58 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.48 | 2023 | Livalo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $16.59 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $16.41 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Idorsia Pharmaceuticals US INC | $14.39 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Duffell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.